Substance Abuse Pre-Treatment Screening Study
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine Abuse; Cocaine Dependence; Opiate Dependence; Alcohol Dependence; Substance Abuse
Intervention: modafinil (Drug); d-amphetamine (Drug); L-Dopa (Drug); Naltrexone (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Joy M. Schmitz, PhD, Principal Investigator, Affiliation: The University of Texas Health Science Center, Houston
Frederick G Moeller, MD, Principal Investigator, Affiliation: The University of Texas Health Science Center, Houston
Angela L Stotts, PhD, Principal Investigator, Affiliation: The University of Texas Health Science Center, Houston
Overall contact:
Ann Garcia, MA, Phone: 713-500-2804, Email: Ann.D.Garcia@uth.tmc.edu
Summary
The overarching goal of this project is to have a consolidated consent and evaluation
procedure that will lead potential subjects to the most appropriate clinical trial or human
laboratory study (and its consent process) for their presenting concerns or interests. A
second purpose is to have a consolidated intake data base on which secondary analyses can be
conducted.
Clinical Details
Official title: General Evaluation of Eligibility for Substance Abuse/Dependence Research
Study design: Other, Prospective
Primary outcome: Urine Toxicology
Secondary outcome: Demographics
Detailed description:
Approximately 1500 candidates per year will respond to advertisements and will complete
preliminary telephone screening without identifiers. Appropriate candidates will be given
appointment times and on arrival will undergo the consent process for evaluation. A complete
medical, social, psychiatric, and drug use history will be obtained. Subjects fulfilling
general health inclusion requirements will then be offered an appropriate study for which the
specific consent will be obtained. The evaluation period will be no more than one day with
all results evaluated within the two following days. Acceptable candidates will then be
invited to complete the study specific consent.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Willing and able to participate in 3- to 6-month treatment program.
- At least 18 years of age.
- Seeking treatment for substances of abuse including (cocaine, opiates, and alcohol).
- Generally physically healthy.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Mandated by the courts/parole officers to attend treatment.
- Not seeking treatment for substances of abuse.
- Plans to move from the Houston area within the 3- to 6-month treatment period.
- Seeking treatment for a substance for which the TRC has no current trial.
Locations and Contacts
Ann Garcia, MA, Phone: 713-500-2804, Email: Ann.D.Garcia@uth.tmc.edu
University of Texas Medical School- Houston, Dept. of Psychiatry Mental Sciences Institute, Houston, Texas 77030, United States; Recruiting
Ann Garcia, MA, Phone: 713-500-2804, Email: Ann.D.Garcia@uth.tmc.edu
Rhian W Farley, MBA, Phone: 713-500-2639, Email: Rhian.farley@uth.tmc.edu
Frederick G Moeller, M.D., Principal Investigator
Additional Information
Starting date: October 2005
Ending date: May 2010
Last updated: August 7, 2008
|
